Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Non Operating Income (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Non Operating Income for 3 consecutive years, with -$4.1 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Non Operating Income rose 8.35% year-over-year to -$4.1 million, compared with a TTM value of -$219000.0 through Dec 2024, down 1745.01%, and an annual FY2024 reading of -$219000.0, down 1745.01% over the prior year.
  • Non Operating Income was -$4.1 million for Q4 2024 at Oramed Pharmaceuticals, up from -$15.4 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $14.2 million in Q2 2024 and bottomed at -$15.4 million in Q3 2024.
  • Average Non Operating Income over 3 years is $92257.0, with a median of $1.0 million recorded in 2022.
  • Peak annual rise in Non Operating Income hit 474.41% in 2024, while the deepest fall reached 3644.83% in 2024.
  • Year by year, Non Operating Income stood at $1.0 million in 2022, then tumbled by 534.04% to -$4.5 million in 2023, then grew by 8.35% to -$4.1 million in 2024.
  • Business Quant data shows Non Operating Income for ORMP at -$4.1 million in Q4 2024, -$15.4 million in Q3 2024, and $14.2 million in Q2 2024.